Full text
3/2026
vol. 22
Editorial
Defining the prognostic role of FIB-4 in heart failure and coronary artery disease: moving towards a multimarker approach to cardiovascular risk prediction
Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
Adv Interv Cardiol 2026; 22, 3 (85): 342–344
Data publikacji online: 2026/09/30
- Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
- Ratti C, Malaguti M, Emanuele D, et al. Understanding MASLD – from molecular pathogenesis to cardiovascular risk: a concise review for the clinical cardiologist. Atherosclerosis 2025; 409: 120495.
- Georgiopoulos G, Athanasopoulos S, Mavraganis G, et al. Incremental value of blood-based markers of liver fibrosis in cardiovascular risk stratification. J Clin Endocrinol Metab 2025; 110: 1115-27.
- Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics 2021; 11: 98.
- Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 Index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol 2022; 117: 453-61.
- Zhang J, Li L, Lin L, et al. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD. BMC Public Health 2025; 25: 2747.
- Yan Z, Liu Y, Li W, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Eur J Clin Invest 2022; 52: e13855.
- Alcântara RWA, Oliveira VMR, Schettino Samad N, et al. Can the FIB-4 index predict mortality in patients with coronary artery disease? A systematic review and meta-analysis. Curr Probl Cardiol 2026; 51: 103350.
- Oksen D, Gecit MH, Bulat Z, et al. Comparative prognostic performance of the FIB-4 index versus SYNTAX and GRACE scores in predicting major cardiovascular events in acute coronary syndrome. Adv Interv Cardiol 2025; 21: 332-40.
- Gorur M, Satar S, Acehan S, et al. FIB-4, a surrogate marker of liver fibrosis, predicts mortality and adverse events after acute myocardial infarction. Intern Emerg Med 2026; 21: 1807-16.
- Serra A, Palmieri E, Burzo ML, et al. FIB-4 index as a non-invasive biomarker of congestion and prognosis in heart failure. J Clin Med 2026; 15: 4448.
- Ren X, Li L, Liu F, Zhu Y. Association between fibrosis-4 index and 30-day all-cause mortality in critically ill patients hospitalised with acute heart failure: a retrospective cohort study from the MIMIC-IV database. Adv Interv Cardiol 2026; 22: 387-95.
- Gao H, Chai L, Meng X. FIB-4 index and adverse outcomes of coronary artery disease: a systematic review and meta-analysis. Adv Interv Cardiol 2026; 22: 345-60.
- Goodheart RH, Ayonrinde OT. Connecting the dots: hepatic steatosis as a central player in the choreography of the liver-cardiovascular-kidney-metabolic syndrome. Heart Lung Circ 2025; 34: 1050-9.
- Gaggini M, Minichilli F, Gorini F, et al. FIB-4 Index and neutrophil-to-lymphocyte-ratio as death predictor in coronary artery disease patients. Biomedicines 2022; 11: 76.
- Vassalle C. New biomarkers and traditional cardiovascular risk scores: any crystal ball for current effective advice and future exact prediction? Clin Chem Lab Med 2018; 56: 1803-5.
- Vassalle C, Xiao J, Sabatino L. Editorial: relationship between cardiovascular disease and other chronic conditions. Front Cardiovasc Med 2022; 9: 875551.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
